go-v.orgdoi

Histone deacetylase inhibition up-regulates MHC class I to facilitate cytotoxic T lymphocyte-mediated tumor cell killing in glioma cells

Ting Sun, Yanyan Li, Wei Yang, Haibin Wu, Xuetao Li, Yu-lun Huang, Youxin Zhou, Ziwei Du · Journal of Cancer · 2019

  • DOI 10.7150/jca.34471
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2019

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2019

Abstract

Background: Immune cells recognize tumor antigens presented on major histocompatibility complex class I (MHC-I) molecule.

Increase of MHC-I molecular expression makes tumor cells more susceptible to lysis by immune cells.Methods: Tumor lysate vaccine was prepared to damage glioma cells including cell lines and primary cultured cells from surgical samples.The enhanced effect of histone deacetylase inhibitors (HDACi) to tumor lysate vaccine was observed.The expressions of MHC-I pathway molecules were detected by flow cytometry and western blot after HDACi treatment.Cell apoptosis and cell lysis were measured following blocking cytotoxic T lymphocyte (CTL) pathway.Tumor size and mice survival were analyzed in combinative treatment with HDACi and tumor lysate.Results: HDACi up-regulated the expressions of MHC-I pathway molecules, and enhanced the recognition and killing of immune cells, which was activated by tumor lysate.Activated antigen specific immune responses regulated CTL activity, and HDACi promoted immune response through cytotoxic effect of CTL.Anti-tumor effect of tumor lysate pulse immunogenicity in vivo was elevated by HDACi due to up-regulation of antigen presentation.Conclusions: Our study showed that HDACi enhanced recognition of glioma cell by immune cells and sensitivity of tumor immunotherapy, and improved the anti-tumor effect of tumor lysate vaccine through activating CTL immune response.These pharmacological molecular mechanisms of increasing immune recognition suggest that epigenetic modulation is a promising strategy for sensitizing immunotherapy for glioma treatment.

Open the resolved locator · 10.7150/jca.34471

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 21:51 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v10p5638.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.